Welcome to VAPGuard
Join us in saving millions of lives and billions of dollars – with simple, sound science
Ventilator-Associated Pneumonia
Every year, hospitals spend over 1.5 billion dollars treating ventilator-associated pneumonia (VAP), a hospital-acquired infection caused by bacteria migrating from an intubated patient’s mouth into their lungs, causing respiratory distress and leading to sepsis.
VAPGuard is a novel attachment to endotracheal tubes that utilizes the power of visible blue light to disinfect the oral microbiome - with over 75% effectiveness - in a selective, non-mutagenic manner.
In this way, the VAPGuard provides a safe, cheap, passive, low-maintenance, and highly effective solution that can be easily integrated into current patient care workflows, simultaneously improving treatment outcomes and significantly reducing hospital care costs.
Key Advantages
Unique
The VAPGuard is one of the few treatments for the VAP prevention market.
Resistance-free
Our visible blue light technology has been shown in clinical settings to not result in bacterial resistance nor mutations, unlike antibiotic solutions out there on the market
Low Cost
A small $150 purchase of a VAPGuard would result in savings of up to $50,000 per VAP case.
Our Solution
VAPGuard's innovative technology selectively targets the harmful bacterial strains that cause VAP, with no risk of mutation, resistance, or irritation.
Our ring-like attachment clasps onto ventilator tubes in a way that is tight but constricting of the airways. Blue LEDs in the 405 nm wavelength emit light throughout the oral cavity.
Partners
.png)
